Osman Mohammed Najeeb, Dunlap Mark E
Research Service, 151W, Louis B. Stokes Cleveland Veterans Affairs Medical Center, 10701 East Boulevard, Cleveland, OH 44106, USA.
Curr Cardiol Rep. 2005 May;7(3):196-203. doi: 10.1007/s11886-005-0077-4.
Heart failure (HF) and pulmonary hypertension (PH) coexist frequently and contribute to each other. Because PH often is an insidious disease, the cornerstone of management is the early identification and treatment of its underlying causes, such as left-sided heart disease, left to right shunts, and pulmonary disorders. A practical clinical classification has been proposed by the Third World Symposium on Pulmonary Arterial Hypertension for the purpose of diagnosis and treatment of PH. Thromboembolic pulmonary hypertension should always be considered. Recent studies using vasodilators such as prostacyclins and endothelin antagonists give new hope in the otherwise poor prognosis of idiopathic pulmonary arterial hypertension and its related conditions. Despite optimum medical management, transplantation (lung/heart-lung) remains the choice in severely symptomatic patients.
心力衰竭(HF)和肺动脉高压(PH)常并存且相互影响。由于PH往往是一种隐匿性疾病,治疗的关键在于早期识别并治疗其潜在病因,如左心疾病、左向右分流以及肺部疾病。第三届世界肺动脉高压研讨会提出了一种实用的临床分类方法,用于PH的诊断和治疗。血栓栓塞性肺动脉高压应始终予以考虑。最近使用前列环素和内皮素拮抗剂等血管扩张剂的研究为特发性肺动脉高压及其相关病症原本不佳的预后带来了新希望。尽管采取了最佳的药物治疗,但对于症状严重的患者,移植(肺/心肺)仍是首选。